Foreign investors are stepping up acquisitions of Japanese drug makers. Under the Foreign Exchange and Foreign Trade Act (FEFTA), such…
REGULATORY
Sept. Drug Price Settlement Rate at 92.6% as Big Hospitals, Pharmacies Take Quantum Leap
A health ministry survey found that pharmaceutical wholesalers had agreed on delivery drug prices with customer healthcare providers for 92.6% of their transactions as of the end of September, six months after the FY2014 NHI price revision, Jiho has learned.…
To read the full story
Related Article
- MHLW Official Says Penalty Rule Needs Review, Frowns on Sanguine Outlook for Annual Drug Price Cut
November 17, 2014
- MHLW Official Says Price Settlement Rate Apparently Topped 90% at End of Sept., but Annual Revisions Unrealistic for “Exhausted” Wholesalers
October 28, 2014
- Drug Price Settlement Rate Might Hit 70% in September: Wholesaler Exec
September 3, 2014
Related LEXICON
REGULATORY
- Pharmacies, Wholesalers Split on Weekend Deliveries at Chuikyo
September 18, 2025
- Generic Firms Push Reform to Ensure Stability, Wholesalers Seek End to Off-Year Cuts
September 18, 2025
- FIRM Calls for Pricing Overhaul to Reflect Unique Benefits of Regenerative Therapies
September 18, 2025
- FPMAJ Urges Blanket Drug Price Hikes to Offset Inflation: FY2026 Reform Talks
September 18, 2025
- MHLW Orders Label Revision for Imdelltra over CRS Risks
September 18, 2025
MSD’s new pulmonary arterial hypertension (PAH) therapy Airwin (sotatercept) hit the Japanese market in mid-August. It’s the kind of launch…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…